NUVB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nuvation Bio Inc (NUVB) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong revenue growth, promising drug performance, and undervaluation by analysts suggest significant upside potential. Despite short-term technical and sentiment neutrality, the long-term prospects make it a solid investment.
The MACD is positive at 0.087, indicating bullish momentum, but it is contracting. RSI is at 67.76, in the neutral zone, showing no overbought or oversold conditions. Moving averages are converging, suggesting no clear trend. The stock is trading near its R1 resistance level of 5.213, with key support at 4.514.
IBTROZI® demonstrated strong clinical results with an 89.8% objective response rate and high efficacy in managing brain metastases.
Analysts highlight the $650M+ opportunity for IBTROZI and long-term upside potential for the company's pipeline.
Revenue growth of 633.06% YoY in Q4 2025 indicates strong business momentum.
Net income and EPS declined significantly YoY in Q4 2025, reflecting profitability challenges.
No recent insider or hedge fund buying activity, indicating neutral sentiment from key stakeholders.
In Q4 2025, revenue surged by 633.06% YoY to $41.87M, driven by strong product uptake. However, net income dropped by 25.99% YoY to -$36.59M, and EPS fell by 26.67% YoY to -0.11, highlighting ongoing profitability challenges. Gross margin improved significantly to 96.94%, up 270.28% YoY, reflecting operational efficiency.
Analysts are mixed but leaning positive. RBC Capital raised the price target to $13 and maintains an Outperform rating, citing strong uptake of IBTROZI and undervaluation of the company's assets. Truist also raised its target to $13 with a Buy rating. UBS lowered its target to $7 but maintained a Neutral rating.
